Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 3, 2016
Trial Designs and Characteristics in Laser Studies in Dermatology: A Systematic ReviewMarie Grabas, Monica Dinulescu, Catherine Droitcourt, et al.
Case Reports in Dermatology|November 28, 2012
Enoxaparin-Induced DRESS SyndromeSophie Ronceray, Monica Dinulescu, François Le Gall, et al.
Melanoma Research|April 27, 2021
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodiesAlexandra Frelau, Eva Jali, Boris Campillo-Gimenez, et al.
The British Journal of Dermatology|February 10, 2023
The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanomaFlorence Poizeau, Frédéric Balusson, Florian Lemaitre, et al.
The Journal of Investigative Dermatology|March 26, 2017
Do the Side Effects of BRAF Inhibitors Mimic RASopathies?Alicia Sfecci, Alain Dupuy, Monica Dinulescu, et al.
Journal of the American Academy of Dermatology|November 30, 2020
Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective studyFrédéric Jaouen, Thibault Kervarrec, Agnès Caille, et al.
Journal of the National Cancer Institute|March 7, 2022
The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving ImmunotherapyFlorence Poizeau, Sandrine Kerbrat, Frédéric Balusson, et al.
The Journal of Investigative Dermatology|October 13, 2020
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017Florence Poizeau, Sandrine Kerbrat, André Happe, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Targeted Oncology|November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialCéleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Pageof 3